Abeona Therapeutics Inc (NASDAQ:ABEO) has received a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the stock. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $16.83.
A number of analysts recently issued reports on the company. Maxim Group restated a “buy” rating and issued a $14.00 price target on shares of Abeona Therapeutics in a research report on Friday, March 10th. Zacks Investment Research downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 14th. HC Wainwright set a $20.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, February 6th. Jefferies Group LLC started coverage on Abeona Therapeutics in a research report on Friday, January 6th. They set a “buy” rating and a $11.00 target price for the company. Finally, FBR & Co reiterated an “outperform” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research report on Friday, February 17th.
WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/04/21/abeona-therapeutics-inc-abeo-receives-average-recommendation-of-buy-from-analysts-updated-updated.html.
Several hedge funds have recently added to or reduced their stakes in ABEO. A.R.T. Advisors LLC acquired a new stake in Abeona Therapeutics during the fourth quarter valued at $117,000. Tudor Investment Corp Et Al acquired a new stake in Abeona Therapeutics during the fourth quarter valued at $162,000. Allianz Asset Management AG acquired a new stake in Abeona Therapeutics during the fourth quarter valued at $236,000. RTW Investments LLC acquired a new stake in Abeona Therapeutics during the third quarter valued at $116,000. Finally, Highbridge Capital Management LLC increased its stake in Abeona Therapeutics by 108.1% in the fourth quarter. Highbridge Capital Management LLC now owns 551,800 shares of the biopharmaceutical company’s stock valued at $2,676,000 after buying an additional 286,657 shares during the period. Institutional investors and hedge funds own 17.79% of the company’s stock.
Shares of Abeona Therapeutics (NASDAQ:ABEO) remained flat at $5.20 during mid-day trading on Monday. The company had a trading volume of 124,554 shares. The company’s 50 day moving average is $5.02 and its 200-day moving average is $5.65. The company’s market cap is $209.33 million. Abeona Therapeutics has a 12 month low of $2.27 and a 12 month high of $9.44.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Friday, March 31st. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.05. The company earned $0.26 million during the quarter, compared to the consensus estimate of $0.19 million. Abeona Therapeutics had a negative return on equity of 26.65% and a negative net margin of 2,029.60%. Equities analysts forecast that Abeona Therapeutics will post ($0.63) earnings per share for the current year.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
What are top analysts saying about Abeona Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abeona Therapeutics Inc and related companies.